https://kuraoncology.com/wp-content/uploads/Erba_video_1_thumbnail.png
1018
2000
Emily Hennes
/wp-content/uploads/kura-logo.svg
Emily Hennes2023-12-20 16:26:052023-12-20 16:43:11Dr. Erba discusses the KOMET-001 Phase 1b safety and tolerability data of ziftomenib, a menin inhibitor, for patients with R/R NPM1-m AML
https://kuraoncology.com/wp-content/uploads/Erba_video_2_thumbnail.png
1166
2292
Emily Hennes
/wp-content/uploads/kura-logo.svg
Emily Hennes2023-12-19 16:47:432023-12-20 16:48:26Dr. Erba offers insight into the KOMET-007 Phase 1 trial and rationale for investigating ziftomenib in combination with standards of care for the treatment of patients with newly diagnosed or R/R NPM1-m or KMT2A-r AML
https://kuraoncology.com/wp-content/uploads/Erba_video_3_thumbnail.png
1172
2288
Emily Hennes
/wp-content/uploads/kura-logo.svg
Emily Hennes2023-12-18 16:50:412023-12-20 16:50:53Dr. Erba explains the different combinations KOMET-008 will evaluate and how it differs from KOMET-007
https://kuraoncology.com/wp-content/uploads/Erba_video_4_thumbnail.png
1166
2292
Emily Hennes
/wp-content/uploads/kura-logo.svg
Emily Hennes2023-12-17 16:52:422023-12-20 16:52:53“Project Optimus encourages optimal biological dosing rather than maximally tolerated dosing.” — Harry Erba, MD, PhD
https://kuraoncology.com/wp-content/uploads/Erba_video_5_thumbnail.png
1172
2286
Emily Hennes
/wp-content/uploads/kura-logo.svg
Emily Hennes2023-12-16 16:56:012023-12-20 16:56:13Dr. Erba provides an overview of the KOMET clinical trial program
Scroll to top